Home › Schizophrenia › Ohio
Schizophrenia clinical trials in Ohio
18 studies for Schizophrenia are looking for participants at sites in Ohio.
Cities in Ohio
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0183, Cincinnati
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 28, 2026 · NCT07686263NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Sites, North Canton
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07114874Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- University of Cincinnati Medical Center, Cincinnati
- Charak Center for Health and Wellness, Garfield Heights
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 25, 2026 · NCT06229210NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, North Canton
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07105098A Study of Brenipatide in Adult Participants With Schizophrenia
- Insight Clinical Trials, Independence
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Sep 22, 2026 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- University of Cincinnati Cancer Institute, Cincinnati
- Local Institution - 0148, Cincinnati
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 22, 2026 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Neuro-Behavioral Clinical Research, Canton
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 9, 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- University of Cincinnati Dept of Psychiatry and Behavioral Neuroscience, Cincinnati
RecruitingPhase 3
Ages 13 to 17 · All sexes · Updated Sep 4, 2026 · NCT07288567A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, North Canton
- Clinical Site, West Chester
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 1, 2026 · NCT07459647Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Westlake Brain Health, Westlake
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07101094Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0031, Mason
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07379827REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
- Case Western Reserve University, Cleveland
Recruiting
Ages 18 to 50 · All sexes · Updated Aug 17, 2026 · NCT07006935Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Cincinnati
- Alkermes Investigator Site, West Chester
RecruitingPhase 3
Ages 10 to 17 · All sexes · Updated Aug 14, 2026 · NCT05303064Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Neuro-Behavioral Clinical Research, North Canton
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 27, 2026 · NCT07363577A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Neuro-Behavioral Clinical Research, North Canton
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Jun 23, 2026 · NCT07191483Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
- Harding Hospital, Columbus
Recruiting
Ages 15 to 35 · All sexes · Updated Feb 25, 2026 · NCT04368039Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
- Vanda Investigational Site, Cincinnati
- Vanda Investigational Site, Garfield Heights
- Vanda Investigational Site, Westlake
RecruitingPhase 4
Ages 12 to 17 · All sexes · Updated Mar 4, 2025 · NCT05648591From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.